No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Incorporated in 2012 and headquartered in Carlton, Australia, 4DMedical Limited operates as a medical technology enterprise across Australia and the United States. The company primarily focuses on bringing to market its innovative XV Technology, an advanced system for four-dimensional lung imaging. Beyond this core offering, its suite of products includes a software-as-a-service (SaaS) delivery model, specialized XV lung ventilation analysis software, and Permetium—a preclinical imaging system designed to quantify regional changes in pulmonary function. Additionally, the firm provides the AccuVent 200, a ventilator tailored for small animals.
www.4dmedical.comNo one on the platform currently holds 4DX.AX.
No tracked institution reports a position in 4DX.AX as of their last filing.
No one on the platform has traded 4DX.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 20.6% | 100.7% | ||||
| Profit Margin % | -2895.1% | -2215.6% | -23060.4% | |||
| Free Cash Flow Margin % | -456.3% | -1564.0% | -18796.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $22M | +167.2% | $-0.06 | $-0.06–$-0.05 | — | 1 |
| 2028 | $57M | +157.2% | $-0.01 | $-0.02–$0.00 | — | 2 |
| 2029 | $99M | +72.8% | $0.04 | $0.01–$0.08 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-28 | $-0.04 | $0.22 | +666.0% |
| 2026-02-26 | $-0.04 | $-0.26 | -615.5% |
| 2025-03-03 | $-0.04 | $-0.03 | +22.5% |
| +2.37% |
| $160M |
| — |
| HLS.AXHealius Limited | $0.46 | +7.06% | $330M | — |
| IDX.AXIntegral Diagnostics Limited | $2.31 | +0.43% | $862M | — |
Source: Financial Modeling Prep · peers by sector/industry